Tag: Insys Therapeutics

StaffAugust 8, 2018
daily_hit004-1280x533.png
BusinessDaily Hit

The Daily Hit: August 8, 2018

7min00
It’s time for your Daily Hit of cannabis financial news for August 8, 2018: On The Site Insys Therapeutics Inc. Insys Therapeutics Inc. (INSY) delivered its earnings today after the market close and following an earlier announcement that it had settled with the Department of Justice. Insys said that it had agreed to pay $150 million over five years and […]
CONTINUE READING
Debra BorchardtAugust 8, 2018
fallingstock.jpg
Business

Insys Therapeutics Misses Earnings, Revenue Estimates As Stock Falls In After Hours Trading

4min00
Insys Therapeutics (INSY) delivered its earnings today after the market close and following an earlier announcement that it had settled with the Department of Justice. Insys said that it had agreed to pay $150 million over five years and “with the potential for contingency-based payments associated with certain events that, if they were to occur, management estimates would […]
CONTINUE READING
Debra BorchardtJuly 30, 2018
daily_hit004-1280x533.png
BusinessDaily Hit

The Daily Hit: July 30, 2018

4min02
It’s time for your Daily Hit of cannabis financial news for July 30, 2018. On The Site Scythian Biosciences Last month Scythian Biosciences agreed to sell its interests and assets in Argentina, Columbia, and Jamaica to Aphria Inc. in a deal valued at $193 million. Now the company is taking that money to enter the Florida Medical Marijuana market in a deal […]
CONTINUE READING
William SumnerFebruary 27, 2018
epidiolex-cannabidiol-or-cbd-bottle-and-packaging-1280x853.jpg
Business

GW Pharmaceuticals Granted Orphan Drug Status By European Agency

3min00
GW Pharmaceuticals plc (GWPH), a biopharmaceutical company dedicated to developing cannabis-based pharmaceuticals, announced today cannabidiol (CBD) has been granted orphan drug status by the European Medicines Agency (EMA) for the treatment of tuberous sclerosis (TS). Orphan drug designation by the EMA is meant for medicines used to treat rare diseases, as defined by no more […]
CONTINUE READING
William SumnerFebruary 2, 2018
shutterstock_723490090-1280x1036.jpg
Business

New York Attorney General Sues INSYS Therapeutics For Deceptive, Illegal Practices

4min00
INSYS Therapeutics, Inc. (INSY), a manufacturer of pharmaceutical cannabinoids and spray technology, has once again found itself in legal hot water. On Feb. 1, 2018, New York Attorney General Eric Schneiderman filed a lawsuit against the company, alleging that INSYS deceptively promoted its fentanyl-based cancer pain medicine, Subsys. Seeking $75 million in penalties, Schneiderman claims […]
CONTINUE READING
Debra BorchardtNovember 2, 2017
Insys.jpg
BusinessPublic

Insys Therapeutics Delivers Third Quarter Earnings Amid Bribery Scandal

3min00
Insys Therapeutics reported its third-quarter earnings as the scandal-ridden biotech company missed revenue and earnings estimates. Net revenues of $30.7 million fell short of analysts estimates as calculated by Yahoo! Finance by $6 million and fell from last year’s $57.8 million as the company noted that the net revenues were impacted by $5 million due to […]
CONTINUE READING

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis

READ MORE
Recent Tweets
Company

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.